Skip to main content

Research Repository

Advanced Search

Survival Outcomes in Older Women with Oestrogen-Receptor-Positive Early-Stage Breast Cancer: Primary Endocrine Therapy vs. Surgery by Comorbidity and Frailty Levels

Wang, Yubo; Steinke, Douglas; Gavan, Sean P.; Chen, Teng-Chou; Carr, Matthew J.; Ashcroft, Darren M.; Cheung, Kwok-Leung; Chen, Li-Chia

Survival Outcomes in Older Women with Oestrogen-Receptor-Positive Early-Stage Breast Cancer: Primary Endocrine Therapy vs. Surgery by Comorbidity and Frailty Levels Thumbnail


Authors

Yubo Wang

Douglas Steinke

Sean P. Gavan

Teng-Chou Chen

Matthew J. Carr

Darren M. Ashcroft

Li-Chia Chen



Abstract

Primary endocrine therapy (PET) offers non-surgical treatment for older women with early-stage breast cancer who are unsuitable for surgery due to frailty or comorbidity. This research assessed all-cause and breast cancer-specific mortality of PET vs. surgery in older women (≥70 years) with oestrogen-receptor-positive early-stage breast cancer by frailty and comorbidity levels. This study used UK secondary data to analyse older female patients from 2000 to 2016. Patients were censored until 31 May 2019 and grouped by the Charlson comorbidity index (CCI) and hospital frailty risk score (HFRS). Cox regression models compared all-cause and breast cancer-specific mortality between PET and surgery within each group, adjusting for patient preferences and covariates. Sensitivity analyses accounted for competing risks. There were 23,109 patients included. The hazard ratio (HR) comparing PET to surgery for overall survival decreased significantly from 2.1 (95%CI: 2.0, 2.2) to 1.2 (95%CI: 1.1, 1.5) with increasing HFRS and from 2.1 (95%CI: 2.0, 2.2) to 1.4 (95%CI 1.2, 1.7) with rising CCI. However, there was no difference in BCSM for frail older women (HR: 1.2; 0.9, 1.9). There were no differences in competing risk profiles between other causes of death and breast cancer-specific mortality with PET versus surgery, with a subdistribution hazard ratio of 1.1 (0.9, 1.4) for high-level HFRS (p = 0.261) and CCI (p = 0.093). Given limited survival gains from surgery for older patients, PET shows potential as an effective option for frail older women with early-stage breast cancer. Despite surgery outperforming PET, surgery loses its edge as frailty increases, with negligible differences in the very frail.

Citation

Wang, Y., Steinke, D., Gavan, S. P., Chen, T.-C., Carr, M. J., Ashcroft, D. M., …Chen, L.-C. (2024). Survival Outcomes in Older Women with Oestrogen-Receptor-Positive Early-Stage Breast Cancer: Primary Endocrine Therapy vs. Surgery by Comorbidity and Frailty Levels. Cancers, 16(4), Article 749. https://doi.org/10.3390/cancers16040749

Journal Article Type Article
Acceptance Date Feb 7, 2024
Online Publication Date Feb 11, 2024
Publication Date Feb 2, 2024
Deposit Date Jul 11, 2024
Publicly Available Date Jul 11, 2024
Journal Cancers
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 16
Issue 4
Article Number 749
DOI https://doi.org/10.3390/cancers16040749
Keywords Cancer Research; Oncology
Public URL https://nottingham-repository.worktribe.com/output/31453383
Publisher URL https://www.mdpi.com/2072-6694/16/4/749